DRMA — Dermata Therapeutics Balance Sheet
0.000.00%
- $2.70m
- -$1.96m
- 13
- 47
- 19
- 14
Annual balance sheet for Dermata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.53 | 10.8 | 6.24 | 7.44 | 3.16 |
| Net Total Receivables | — | — | 0.013 | 0.008 | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.605 | 11.6 | 6.94 | 7.98 | 3.53 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0 | — | — | — | — |
| Total Assets | 0.605 | 11.6 | 6.94 | 7.98 | 3.53 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 3.78 | 1.52 | 0.923 | 1.62 | 1.97 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 3.78 | 1.52 | 0.923 | 1.62 | 1.97 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -3.18 | 10.1 | 6.02 | 6.36 | 1.56 |
| Total Liabilities & Shareholders' Equity | 0.605 | 11.6 | 6.94 | 7.98 | 3.53 |
| Total Common Shares Outstanding |